A total of 38 autochthonous cases of chikungunya have been confirmed in France, in the regions of Provence-Alpes-Côte d’Azur, Corsica, Occitanie, Auvergne-Rhône-Alpes, Grand Est, and Nouvelle-Aquitaine, illustrating the risk of local transmission. In addition, 833 imported cases have been reported, many of them from travelers returning from Réunion and Mayotte since May 2025. A recent study has shown that the virus infects chondrocytes, potentially contributing to chronic musculoskeletal disorders. Vaccines have now been approved in the U.S. and Europe.
Chikungunya is a viral disease transmitted by Aedes mosquitoes (especially Aedes aegypti and Aedes albopictus), present in many tropical and subtropical regions. It typically presents with a sudden high fever and severe joint pain, which can persist for weeks or even months. There is no specific antiviral treatment, but two vaccines have been authorized in certain countries. Prevention relies on avoiding mosquito bites (using repellents, wearing appropriate clothing, and mosquito nets) and controlling mosquito breeding sites. Vaccination may be considered for individuals at high risk of exposure. Epidemiological surveillance and early detection are essential to prevent the geographic spread of the virus.
